COVID-19: Our series of regulatory legislation trackers for the Life Sciences & Healthcare industry - UAE
Written By
Partner, Melissa Murray and Senior Associate, Surabhi Singhi provided content for the United Arab Emirates.
COVID-19 presents an unprecedented challenge to the global life sciences industry. Members of Bird & Bird's International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships with regulatory bodies, have worked together to provide an update in the form of a Q&A for each of the countries we are located. This update aims to provide guidance on the responses of EU, Asia-Pac and UAE regulators in the areas of clinical trials, medical devices, market access, public procurement and compulsory licensing.
Latest insights
More Insights
Denmark: Supreme Court judgement regarding salary during suspension in connection with the summary dismissal of a municipal employee
Sep 13 2024
A spotlight on Australia Privacy Reform: A long awaited first step – First tranche privacy reforms introduced to Parliament
Sep 12 2024
NIS2 is about to become a reality in Denmark: What should your organisation be aware of?
Sep 12 2024